Literature DB >> 3942398

[Head and neck cancer: choice of treatment in relation to clinical and pathological findings].

I Ono.   

Abstract

There are several organs in the head and neck region, and cancers arising in this region show a variety of histological findings. Therefore, the first choice of treatment for head and neck cancer should be decided according to sites of origin, clinical staging and pathological findings. Furthermore, the head and neck region plays very important roles in speaking, eating, and esthetic functions. The principles of treatment for head and neck cancer are as follows. As regards carcinoma of the larynx and oral cavity, radiotherapy is usually adopted when the carcinoma is small and limited, and surgical treatment is recommended in cases of rather advanced carcinoma. In the treatment of carcinoma of the nasopharynx, radiotherapy is undoubtedly the first choice of treatment and chemotherapy is combined in advanced cases. In the case of carcinoma of the methopharynx, surgical treatment is advisable for well differentiated squamous cell carcinoma and radiotherapy for poorly differentiated squamous cell carcinoma. For carcinoma of the hypopharynx, surgical treatment is advisable except for T1 cases of the pyriform sinus. Combination of radiotherapy, arterial chemotherapy and limited surgery is generally accepted as the method of treatment for maxillary sinus carcinoma.

Entities:  

Mesh:

Year:  1986        PMID: 3942398

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  An outcome of Surgically Treated Head and Neck Cancer in one of the tertiary Referral Center in the East Coast of Malaysia: A 6-year Retrospective Analysis.

Authors:  Kahairi Abdullah; Raja Ahmad Raja Lope Ahmad; Zamzil Amin Asha'ari; Mohd Sayuti Razali; Wan Islah Leman
Journal:  Malays J Med Sci       Date:  2014-07

2.  Can a genetic signature for metastatic head and neck squamous cell carcinoma be characterised by comparative genomic hybridisation?

Authors:  H S Patmore; J N E Ashman; L Cawkwell; A MacDonald; N D Stafford; J Greenman; N E Ashman James
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.